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Abstract of the Thesis 
 
Engineered proteins with activating module for reprogramming of cell signaling pathway 
 
by 
 
Lunan Shao 
 
Master of Science in Bioengineering 
University of California, San Diego, 2017 
 
Professor Yingxiao Wang, Chair 
 
 Programmed cell death protein 1 (PD-1) and signal regulatory protein α (SIRPα) 
are receptors that transduce inhibitory signals to negatively regulate effector functions of 
immune cells, which were both utilized by cancers to evade and inhibit the immune 
response. Through protein engineering, integrated sensing and activating proteins 
(iSNAPs) were developed to replace the cytoplasmic domains of PD-1 and SIRPα 
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receptors. With Fyn as the activating module, engineered Fyn-iSNAP replaced the 
cytoplasmic tail of PD-1, which was intended to reprogram PD-1/PD-L1 inhibitory 
signaling into activating Fyn signaling upon ligand binding. However, characterization of 
Fyn-iSNAP in HeLa cells demonstrated that this engineered protein failed to show 
desired functions. In the second chapter, in order to rewire SIRPα/CD47 inhibitory 
pathway, Shp2-iSNAPs and Syk-iSNAPs were developed and used to replace the original 
SIRPα cytoplasmic domain in our previous studies (data not published yet). In order to 
increase gene delivery efficiency, the sizes of the engineered SIRPα-iSNAPs were 
reduced. The expression of the truncated proteins in mouse macrophages led to enhanced 
phagocytosis of opsonized red blood cells (RBCs). Also, human promyelocytic leukemia 
cell derived macrophages (PLDMs) were engineered for the first time using the SIRPα-
Shp2-iSNAPs and its truncated version, which demonstrated enhanced engulfment 
against opsonized RBCs as well as tumor cells. Therefore, these engineered proteins with 
activating module potentially offer a new approach for future cancer immunotherapy.
  
 1 
Chapter 1: The reprogramming of PD-1/PD-L1 inhibitory pathway in T cell with Fyn-
iSNAPs  
1.1 Background 
1.1.1 T-cell activation 
 T-cell activation through T-cell antigen receptor (TCR) is important for effective 
acquired immune response to counteract the invasion of various pathogens. Upon TCR 
engagement with antigen peptides, Src family kinases, Lck and Fyn, are activated, 
leading to phosphorylation of CD3 molecules within the TCR complex [1,2]. 
Subsequently, doubly phosphorylated CD3ζ serves as a docking site for Syk family 
kinase ZAP-70, which leads to activation of ZAP-70 catalytic activity and its 
autophosphorylation [3]. Activated ZAP-70 phosphorylates downstream signaling 
molecules, such as LAT, which can potentially lead to T-cell activation [3,4] 
In order to prevent immune hyperactivation and autoimmunity, T-cell activation 
involves the balance between activating and inhibiting signal [5]. In activated T cell, 
programmed cell death protein 1 (PD-1) is a receptor protein that is transcriptionally 
induced to negatively regulate T-cell activation [6]. PD-1 receptor is a 55 kDa 
transmembrane protein with its extracellular domain consisted of a single Ig-like variable 
domain, and its cytoplasmic domain encodes both immunoreceptor tyrosine-based 
inhibitory motif (ITIM) and an immunoreceptor tyrosine-based switch motif (ITSM) 
[7,8]. PD-1 receptor has two ligands, PD-1 ligand 1 (PD-L1) and PD-1 ligand 2 (PD-L2), 
and the receptor does not have enzymatic activity, but its cytoplasmic domain is the 
binding site for downstream proteins [9,10]. Upon ligand engagement, PD-1 is 
phosphorylated on tyrosine sites within ITIM and ITSM, which bind phosphatase SHP-2 
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that downregulates T cell activation by dephosphorylating CD3ζ chain in TCR and 
preventing recruitment of protein kinase ZAP70 [9].  
1.1.2 Fyn kinase structure 
T-cell activation is mediated through signaling cascades that transduce 
extracellular signals to intracellular responses, which lead to the effector functions of T 
cell. Activation of Fyn is closely involved with these signaling cascades by inducing 
binding of downstream signaling molecules, such as phosphatidylinositol 3-kinase (PI3K) 
and adhesion and degranulation-promoting adaptor protein (ADAP) [11,12]. Recruitment 
of these substrates through Src-homology (SH) domains allows Fyn to initiate and 
regulate diverse lymphocyte effector functions.  
Fyn is 59 kDa non-receptor tyrosine kinase that has four Src-homology (SH) 
domains: the N-terminal SH4 domain, SH3 domain, SH2 domain and a tyrosine kinase 
domain (SH1) [13].  The SH4 domain contains a unique region that has two Cys residues, 
which contribute to Fyn functions [14]. The SH3 domain is consisted by a β-barrel 
structure that serves as a binding site for proline-rich peptide, and the SH2 domain 
specifically interacts with phosphorylated tyrosine sites [15]. The SH3 and SH2 domains 
help mediate the interaction between Fyn and its downstream substrates during 
phosphorylation [15]. 
  Intramolecular interactions among SH domains determine Fyn conformation, 
which regulates Fyn activity by preventing excess kinase activation. At inactive state of 
Fyn, the SH2 domain binds to a phosphorylated regulatory tyrosine site (Tyr531) at C-
terminus, which results in occlusion of the kinase domain by the SH2 and SH3 domains. 
[16-18]. By dephosphorylating Tyr531 or removing this regulatory interaction by 
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competition from another more specific interacting ligand, the SH2 domain disassociates 
from the C-terminus, which exposes the SH1 domain, Fyn kinase becomes active to 
phosphorylate downstream proteins [19].  
 Based on the aforementioned function and structure of Fyn, an engineered protein 
with Fyn kinase as the activating module was developed to replace the original 
cytoplasmic tail of PD-1 receptor, which was intended to rewire the PD-1/PD-L1 
inhibitory signaling pathway in T cells into an activating one and prevent cancer cells 
from evading the immune response. 
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1.2 Results 
 
1.2.1 Development of Fyn-iSNAPs 
To reprogram the downstream signal of PD-1 receptor, the ITIM and ITSM 
domain of PD-1 receptor was replaced by our engineered protein consisted of an 
interacting ligand of Fyn SH2/SH3 domain, fluorescence proteins, and full-length Fyn 
kinase. One of the interacting ligands, L1, in this engineered protein has high affinity of 
binding to Fyn SH2 domain, which was originally found in the hamster middle-sized 
tumor (HmT) antigen [20]. Another ligand, L2, adds a proline-rich region to the N-
terminus of L1, which facilitates the additional binding of the SH3 domain in the purpose 
of further exposing the SH1 domain and activating Fyn kinase. Also, ITAM region from 
CD3ζ1 of TCR was used as one of the ligands, Z1. Even though this ITAM region has 
two tyrosine sites, it has low binding affinity to Fyn SH2 domain [21].  In addition, a 
control group with no ligand region was designed and named as control-Fyn-iSNAP (C-
Fyn-iSNAP). The ligand regions are followed by cyan fluorescent protein, ECFP and 
yellow fluorescent protein, YPet, which can engage in FRET. In previous literature, 
FRET-based biosensors have been developed to visualize molecular dynamics in live 
cells [22]. When two fluorophores are apart, exciting ECFP with 433 nm light allows it to 
emit 476 nm light. However, when ECFP is in close proximity with YPet, the emitting 
light of ECFP is capable of exciting YPet, which results in YPet emitting 530 nm light. 
Following the FRET fluorescence protein pair, it is full-length Fyn kinase with SH 
domains and C-terminus protein sequence intact so that the structure and functions of the 
kinase are largely preserved. Therefore, upon PD-L1 engagement, the ligand in Fyn-
iSNAP gets phosphorylated, and this phosphorylated tyrosine site competes with C-
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terminal phosphorylated Tyr531 for binding to the SH2 domain. Then, it leads to the 
activation of Fyn kinase by exposing SH1 domain and an overall conformational change, 
which brings ECFP and YPet in proximity and results in a FRET/ECFP emission ratio 
change (Figure 1). Thus, when this engineered protein is utilized to replace original 
cytoplasmic domain of PD-1 receptor, it can both help visualize phosphorylation event at 
PD-1 cytoplasmic tail and, at the same time, transduce activating signals that lead to 
effector functions of T cell.  
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Figure 1: The structure and activation of the Fyn-iSNAP. (A) Schematic drawing of the 
Fyn-iSNAP and its intended activation mechanism upon PD-L1 engagement. (B) 
Schematic representation of the Fyn-iSNAP before and after being fused to the truncated 
PD-1 receptor. 
 
1.2.2 Characterization of Fyn-iSNAPs in live mammalian cells 
Fyn-iSNAPs with different ligands as well as a positive control, Z1-ZAP70-
iSNAP (Z1-ZAP70-iSNAP), were transfected into a mammalian cell line, HeLa. Z1-
ZAP70-iSNAP fused with truncated PD-1 reeptor was capable of sensing 
phosphorylation event (data not published yet). Pervanadate (PVD) was used to inhibit 
phosphatase activity within the cells, which increased the level of cellular tyrosine 
phosphorylation [23]. Therefore, PVD treatment can phosphorylate the tyrosine site 
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within the interacting ligands. As shown in Figure 2 and Figure 3, compared to Z1-Fyn-
iSNAP, C-Fyn-iSNAP and the positive control, the cells transfected with L1-Fyn-iSNAP 
and L2-Fyn-iSNAP demonstrated relatively high basal level of FRET/ECFP emission 
ratio before PVD treatment. After adding PVD, all Fyn-iSNAPs showed no significant 
change in FRET/ECFP ratio when Z1-ZAP70-BA showed more than threefold FRET 
ratio change within 30 minutes. Also, for this positive control group, the change began 
between 5-10 minutes after stimulation.  
Even though the cells were plated on glass bottom dish (Cell E&G) coated with 
the same concentration of fibronectin (Sigma), the cells transfected with L1-Fyn-iSNAP 
and L2-Fyn-iSNAP had different morphology compared to the other groups. Most L1- 
and L2-Fyn-iSNAPs transfected cells were flat and elongated, while those transfected 
with Z1-ZAP70-iSNAP, C-Fyn-iSNAP and Z1-Fyn-iSNAP retained their epithelial-like 
shape as shown in Figure 3.  
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Figure 2: The normalized emission ratio time courses of Fyn-iSNAPs in response to 
pervanadate (PVD) treatment in HeLa cells. The time courses of normalized average 
FRET/ECFP ratios of L1-Fyn-iSNAP-Z1 (blue solid circles, n = 10), L2-Fyn-iSNAP 
(magenta squares, n = 10), Z1-Fyn-iSNAP (brown solid triangles, n = 10), C-Fyn-iSNAP 
(green solid triangles, n = 10) and positive control group: Z1-ZAP70-iSNAP (black 
triangles, n = 5) in HeLa cells before and after 20 µM PVD treatment (Arrow at 0 min 
indicates treatment time). The error bars represent the standard error of the mean 
(S.E.M.). Data are showed as mean ± S.E.M..  
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                                  + 0 min         + 10 mins (PVD)   + 35 mins 
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Figure 3: Time-lapse images of HeLa cells expressing Fyn-iSNAPs in response to PVD 
stimulation.These FRET/ECFP ratio images were subtracted by background, and they 
showed HeLa cells transfected with L1-Fyn-iSNAP, L2-Fyn-iSNAP, Z1-Fyn-iSNAP, C-
Fyn-iSNAP and Z1-ZAP7-iSNAP (from top to bottom). The FRET/ECFP ratio in the 
images ranges from 1-5 for Z1-ZAP70-iSNAP and 1-4 for the rest of groups. Scale bar, 5 
µm. 
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1.3 Discussion 
In HeLa cells, all Fyn-iSNAPs showed no FRET/ECFP emission ratio change 
after PVD stimulation compared to their basal level. However, differences in their 
average FRET/ECFP ratio were observed in their original basal level. Since there is no 
tyrosine site at the N-terminus, C-Fyn-iSNAP served as a control construct that captured 
the FRET/ECFP ratio level when the ligand was not phosphorylated within the Fyn-
iSNAPs.  For Z1, which is a low-affinity binding partner of the Fyn SH2 domain but 
high-affinity binding partner of the ZAP70 SH2 domains, its Fyn-iSNAP and ZAP70-
iSNAP showed a FRET/ECFP ratio basal level that was comparable to the negative 
control group. After PVD treatment, Z1-Fyn-iSNAP showed no change, but Z1-ZAP70-
iSNAP showed significant change in the emission ratio. Thus, these results may indicate 
that only after PVD stimulation, the tyrosine sites on Z1 were phosphorylated so that 
there was a conformational change in Z1-ZAP70-iSNAP. However, since phosphorylated 
Z1 had low binding affinity to the Fyn SH2 domain, it may not be able to compete with 
regulatory pTyr531 at C-terminus and to bind to the SH2 domain, which led to no 
FRET/ECFP ratio change. For L1 and L2, which contain a high-affinity binding region to 
the Fyn SH2 domain, their Fyn-iSNAPs demonstrated relatively high FRET/ECFP ratio 
before and after PVD treatment compared to C-Fyn-iSNAPs, and the addition of PVD did 
not increase the ratio further. Therefore, it was likely that the ligand region of L1- and 
L2-Fyn-iSNAPs were easily phosphorylated within HeLa cells and bound to the SH2 
domain by competing with pTyr531 at all time, which could cause conformational changes 
and increased FRET occurrence even before PVD stimulation. Thus, PVD treatment 
could not elicit any FRET/ECFP ratio change since L1 and L2 were already 
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phosphorylated in the HeLa cells. Measuring the phosphorylation level of Fyn-iSNAPs 
before and after PVD stimulation can test this hypothesis. Also, adding a proline-rich 
peptide to the Fyn SH2 domain-binding partner did not cause any difference in 
FRET/ECFP ratio, which means the high-affinity binding partner was the most important 
region in determining the overall structure of L1- and L2-Fyn-iSNAPs and FRET/ECFP 
ratio. 
As mentioned earlier, a difference in the values of FRET/ECFP ratio was 
observed for HeLa transfected with Fyn-iSNAPs with different ligand regions. This 
difference may also indicate the potential of finding a specific ligand that gets 
phosphorylated only after PVD stimulation and has high affinity of binding to the Fyn 
SH2 domain after phosphorylation. With that ligand, truncated human PD-1 fused Fyn-
iSNAP would be able to rewire PD-1/PD-L1 pathway in T cells and contribute to 
immunotherapy for cancers. 
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1.4 Materials & Methods 
1.4.1 DNA construction and plasmids 
LacZ-Fyn-iSNAP was constructed first by using polymerase chain reaction (PCR) 
to obtain the necessary DNA components, which were LacZ, ECFP-YPet FRET pair, 
human Fyn (Figure 1B). The components were assembled into pCBI vector through 
Gibson Assembly (New England Biolabs).  
The LacZ region was replaced by various ligands of Fyn SH domains using 
Golden Gate Assembly (New England Biolabs). The ligand, L1, was EPQYEEIPIYL, 
which contained high-affinity binding partner of Fyn SH2 domain after phosphorylation 
[24]. The sequence of the second ligand, L2, was HSIAGPPVPPREPQYEEIPIYL, which 
had a proline-rich region and the same binding partner as in L1. ITAM region of CD3ζ-
chains of TCR, NQLYNELNLGRREEYDVLDK, constitutes the third ligand for the SH2 
domain of Fyn. All plasmids were purified with the QIAquick Gel Extraction Kit 
(Qiagen) and Miniprep Kit (Qiagen).  
1.4.2 Cell culture and reagents  
HeLa cells were obtained from American Tissue Culture Collection (ATCC) 
(Manassas, VA), and they were cultured in medium containing Dulbecco’s modified 
Eagle medium (DMEM) (Gibco), 10% fetal bovine serum (FBS) (Atlanta Biologicals, 
Lawrenceville, GA), 1x GlutaMAX (Thermo Fisher) and 1x penicillin/streptomycin 
(Invitrogen). They were cultured in 37°C humidified-incubator with 5% CO2. HeLa cells 
were transfected with the plasmids using Lipofectamine 3000 kit (Sigma-Aldrich) 48 
hours before imaging. Cell starvation started 24 hours before imaging by culturing cell 
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with starvation medium containing advanced DMEM (Gibco), 1x GlutaMAX and 1x 
penicillin/streptomycin. 
1.4.3 Image acquisition and analysis  
Before imaging, the cells were plated onto glass-bottom dishes (Cell E&G) coated 
with fibronectin (Sigma) at 10 µg/mL concentration, and the coated dishes were kept at 
37°C for 4 hours before cell plating. During imaging, the plated HeLa cells were 
maintained in the starvation medium at 37°C with CO2 supplemented. The images 
recording the basal level of the cells were taken for at least 10 minutes. Then, cells were 
stimulated with pervanadate, which inhibited phosphatase activity within the cells and led 
to phosphorylation at the ligand region of the Fyn-iSNAP. 
The images were collected with a Nikon eclipse Ti inverted microscope with 100x 
DIC Nikon microscope objective (NA 1.4) used and the MetaMorph 7.8.8.0 software 
(Molecular Devices). Furthermore, the microscope was installed with a 450DRLP 
dichroic mirror, a 420DF20 excitation filter, 475DF40 filter for ECFP and 535DF25 filter 
for YPet (Chroma).      
Image analysis was conducted on Fluocell, which is an image analysis software 
developed at the Wang lab (data not published yet). The fluorescence intensity of non-
transfected HeLa cells was set as the background, which is subtracted from the 
fluorescence signals of the transfected cells. Then, the pixel-by-pixel ratio images of 
FRET/ECFP were displayed in the intensity modified display (IMD) mode. For each 
pixel, the color was determined by the ECFP/FRET ratio, and ECFP fluorescence 
intensity determined the brightness. 
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Chapter 2: The reprogramming of SIRPα/CD47 inhibitory pathway in macrophage with 
SIRPα-iSNAPs  
2.1 Background 
2.1.1 The role of Fcγ receptors in macrophages 
Macrophages are innate immune cells that are capable of eliminating cell debris 
and pathogens by phagocytosis, and this effector function is regulated by a complex 
mechanism involves balance between activating and inhibitory signals. Fcγ receptors 
(FcγRs) are expressed on the surface of macrophages, and they have binding specificity 
towards Fc domain of antibodies, which allows macrophages to bind to infected cells or 
pathogens [25]. This binding is important for the initiation of antibody-dependent cellular 
phagocytosis (ADCP) [26].  FcγRs have an immunoreceptor tyrosine-based activation 
motif (ITAM) in their cytoplasmic domain, and ligation of Fc domain to activating FcγR 
leads to the phosphorylation of ITAM region, which recruits Spleen tyrosine kinase (Syk) 
[27]. Syk phosphorylates and activates downstream molecules, such as PI3K and MAP 
kinase, which leads to an increase in cellular calcium level and eventually promotes 
phagocytosis [28]. Therefore, after monoclonal antibodies (mAbs) against tumor antigens 
were found, such as rituximab and cetuximab, macrophages were capable of engulfing 
and degrading targeted cancer cells in vitro [29]. 
2.1.2 The role of SIRPα receptor in macrophages 
Besides pro-phagocytic signals from activating Fcγ receptors, phagocytosis is also 
regulated by inhibitory surface receptors, such as signal regulatory protein α (SIRPα), 
which negatively regulates the effector function of macrophage. The cytoplasmic domain 
of SIRPα contains inhibitory immunoreceptor tyrosine-based inhibition motifs (ITIMs)
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 [30]. When the extracellular domain of SIRPα interacts with a widely expressed 
transmembrane protein CD47, ITIMs get phosphorylated and bind to the SH2 domain of 
tyrosine phosphatase 1 (SHP1), which activates the phosphatase and initiates a signaling 
cascade that inhibits macrophage phagocytosis [31,32]. Thus, by interacting with 
inhibitory SIRPα receptor, CD47 serves as a “don’t eat me” signal and a sign of “self”, 
which is expressed on majority of normal tissue cells so that the cells will not be the 
targets of phagocytosis [33,34]. However, this CD47-SIRPα pathway is also utilized by 
cancers to evade the immune system by inhibiting macrophage phagocytosis. 
Upregulation of CD47 has been observed on multiple human tumor types, including 
acute and chronic myeloid leukemia, acute lymphoblastic leukemia, glioblastoma, 
hepatocellular carcinoma, ovarian and prostate tumor cells, and many others [35,36].  
This evasion mechanism of utilizing the CD47-SIRPα pathway also offers the 
potential for treating cancers. Monoclonal antibodies directed against CD47 has been 
developed to inhibit the CD47-SIRPα pathway, which blocked the inhibitory signaling 
cascade and have shown tumor eradication of various cancer types in mouse 
xenotransplantation models [35,37,38]. However, hemolysis may occur during anti-CD47 
cancer therapy since human red blood cells (RBCs) express high-level CD47 as well [39].  
Therefore, rewiring CD47-SIRPα pathway in macrophages, combining with 
antibodies that specifically target tumor cells, offers a potential therapeutic strategy for 
cancer therapy with minimal off-target effects. 
2.1.3 Shp2-iSNAP & Syk-iSNAP  
In our previous study, an integrated sensing and activating protein (iSNAP) for 
macrophage phagocytosis was developed with either phosphatase Shp2 or kinase Syk as 
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the activating module, and these engineered proteins were used to replace the original 
SIRPα cytoplasmic domain (data not published yet). The tyrosine phosphatase Shp2 is 
autoinhibited, and its protein tyrosine phosphatase (PTP) domain is occluded by the N-
SH2 domains [40]. Upon binding to a phosphorylated peptide, the N-SH2 domain moves 
away, which exposes the enzymatic domain and results in activated Shp2 [41]. The Shp2-
iSNAP consists of a peptide containing tyrosine site (BTAM), ECFP and YPet 
fluorescent protein pair, and Shp2 without its C-terminal tail subsequently. ECFP and 
YPet can engage in fluorescence resonance energy transfer (FRET). Therefore, upon 
phosphorylation, the BTAM can bind to the N-SH2 domains, which allows ECFP and 
YPet to be in close proximity and leads to FRET/ECFP emission ratio changes. Also, 
when the N-SH2 domains bind to the BTAM, the PTP domain of Shp2 is simultaneously 
exposed, which leads to subsequent phosphatase activity. Therefore, upon CD47 
engagement, SIRPα cytoplasmic domain is phosphorylated at the BTAM region within 
the engineered iSNAP, and instead of transducing anti-phagocytic signals through the 
phosphatase Shp1, SIRPα-Shp2-iSNAP senses phosphorylation at the BTAM region and 
simultaneously promotes macrophage pro-phagocytic Shp2 (data not published yet).  
 Based on the same principle as that of Shp2-iSNAP, Syk-iSNAP utilized Syk as 
the activating module with a sensing peptide derived from the ITAM motif of FcγRIIA 
and the same FRET pair. Instead of inhibiting macrophage phagocytosis via Shp1, the 
engineering SIRPα receptor with Syk-iSNAP promotes phagocytosis via the activation of 
Syk kinase (data not published yet).  
For further research purposes, increasing gene delivery efficiency is needed. 
Preliminary experiments including the lentiviral infection of induced pluripotent stem 
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cells (iPSCs) demonstrated that the delivery of SIRPα-Shp2-iSNAP and SIRPα-Syk-
iSNAP were not efficient due to their DNA sizes. Therefore, in order to characterize and 
utilize these engineered proteins in further applications, the sizes of the engineered 
SIRPα-Shp2-iSNAP and SIRPα-Syk-iSNAP were reduced in this study, and the truncated 
proteins were tested in macrophages to determine if they retain their original capability of 
rewiring SIRPα/CD47 pathway. 
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2.2 Results 
 
2.2.1 Development and characterization of the size-reduced SIRPα-iSNAPs in mouse 
macrophages 
 
 The size-reduction of SIRPα-iSNAPs started with the removal of ECFP and YPet 
flurophore pair since the removal would potentially had no effects on the rewiring and 
activating functions of the engineered proteins.  Thus, ECFP, YPet and the linker between 
them were removed from the original SIRPα-iSNAPs and replaced by flexible peptide 
linkers, such as 17mer, 34mer and EV linker [42,43]. 17mer linker is consisted of 
GSTSGSGKPGSGEGSTK, and 34mer linker has 34 amino acids that are consisted of 
two 17mer linkers [42]. EV linker has 116 amino acids [43]. In order to visualize the 
engineered cells using flow cytometry or imaging, YPet was added at the C-terminus of 
the truncated SIRPα-iSNAPs (Figure 4).  
Figure 4: Schematic drawing of the truncated SIRPα-iSNAP and its intended activation 
mechanism upon CD47 engagement. Upon CD47 engagement, the BTAM/ITAM region 
gets phosphorylated, which leads to the autoinhibitory N-SH2 domains binding to this 
region. Then, the enzymatic domain within Shp2 or Syk will be exposed, which leads to 
Shp2/Syk activation and downstream activating signaling. 
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Functionality of the size-reduced iSNAPs was tested in RAW264.7 macrophages. 
After RBCs with high level of CD47 expression were stained with CellTrackerTM Deep 
Red and opsonized with rabbit anti-hRBC IgG, they were incubated with the 
macrophages. Then, the engulfment efficiency was detected by using flow cytometer. As 
shown in Figure 5, SIRPα-Shp2-iSNAP-34mer, SIRPα-Shp2-iSNAP-EV and SIRPα-Syk-
iSNAP-EV showed higher phagocytosis efficiency compared to the negative control 
group, which was the original full-length SIRPα receptor fused with YPet (SIRPα-FL-
YPet). Since SIRPα-Shp2-iSNAP-17mer did not show a significant difference compared 
to negative control, this experimental group was excluded from subsequent experiments. 
 
 
 
  
 
Figure 5: The phagocytic efficiency of the size-reduced SIRPα-iSNAPs in RAW264.7.  
Bar graph (mean ± S.E.M.) of normalized phagocytic efficiency of RAW264.7 expressing 
the negative control group against opsonized RBCs. **** (P < 0.0001), * (P < 0.05) and 
n.s. (P > 0.05) are from ordinary one way ANOVA. 
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2.2.2 Characterization of the SIRPα-iSNAPs and the size-reduced SIRPα-iSNAPs in 
human macrophages 
At the same time, whether the iSNAP constructs can also enhance the 
phagocytosis of human promyelocytic leukemia cell derived macrophages (PLDMs) was 
examined using HL60. This was the first time that SIRPα-iSNAPs were confirmed to 
express correctly in human PLDMs. Also, by utilizing lentiviral infection and cell sorting, 
a robust and highly efficient approach was developed to obtain engineered macrophages 
from promyelocytic leukemia cells (Figure 6). Then, the phagocytic power of engineered 
PLDMs was tested against opsonized RBCs and non-opsonized RBCs (Figure 6). PLDMs 
with SIRPα-Shp2-iSNAP demonstrated increased phagocytosis efficiency against 
opsonized RBCs compared to native PLDMs and those with anti-phagocytic SIRPα-FL-
YPet, but the PLDMs expressing SIRPα-Shp2-iSNAP did not have enhanced efficiency 
against non-opsonized RBCs. In addition, the phagocytic power of the engineered 
PLDMs against tumor cells was also tested. This experiment used Toledo, a human non-
Hodgkin's lymphoma (NHL) cell line that expresses CD20. The engineered PLDMs with 
SIRPα-Shp2-iSNAP demonstrated increased engulfment of Toledo cells opsonized by 
anti-CD20 antibody (Figure 6C), and the putative mechanism was shown in Figure 7. 
After development of the size-reduced SIRPα-Shp2-iSNAPs, they were 
transduced into HL60 as well. Following cell sorting procedure, HL60 cells expressing 
SIRPα-Shp2-iSNAP-34mer and SIRPα-Shp2-iSNAP-EV were enriched, which then were 
derived into engineered macrophages. Then, the phagocytic power of these engineered 
PLDMs was tested against opsonized RBCs, and the results were shown in Figure 8. 
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Figure 6: The phagocytic efficiency of SIRPα-Shp2-iSNAPs in PLDMs. (A) Bar graph 
(mean ± S.E.M.) of normalized phagocytic efficiency of PLDMs expressing SIRPα-Shp2-
iSNAP against opsonized human RBCs. ** (P < 0.001) and n.s. (P > 0.05) are from 
ordinary one way ANOVA. (B) The comparison of the phagocytosis efficiency of PLDMs 
against opsonized or non-opsonized RBCs. (C) Bar graph (mean ± S.E.M.) of normalized 
phagocytic efficiency of PLDMs expressing SIRPα-Shp2-iSNAP against rituximab-
opsonized Toledo cells. ** (P < 0.001) is from two-tailed Student t-test. 
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Figure 7: Schematic drawing of the engineered macrophage for antibody-mediated tumor 
cell phagocytosis. In native macrophages, upon CD47 ligation, PD-1 receptor transduces 
inhibitory signaling through SHP1, which inhibits FcγR. In previously engineered 
macrophages, SIRPα-iSNAPs not only further promote phagocytosis via Shp2/Syk kinase 
but also utilize FRET within iSNAP to simultaneously report the activation of the 
activating modules. At last, the truncated SIRPα-iSNAPs retain the activating function 
but not the monitoring function. 
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Figure 8: The phagocytic efficiency of SIRPα-Shp2-iSNAPs in PLDMs. Bar graph (mean 
± S.E.M.) of normalized phagocytic efficiency of PLDMs expressing the truncated SIRPα-
Shp2-iSNAP against opsonized human RBCs. **** (P < 0.0001) and n.s. (P > 0.05) are 
from ordinary one way ANOVA. 
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2.3 Discussion 
The size-reduced SIRPα-Shp2-iSNAP demonstrated different levels of 
phagocytosis efficiency against RBCs in macrophages. This increased efficiency of the 
engineered macrophages with SIRPα-Shp2-iSNAP-34mer and SIRPα-Shp2-iSNAP-EV 
was consistent with the previous results of the original SIRPα-iSNAP-Shp2. However, 
SIRPα-Shp2-iSNAP-17mer did not show increased phagocytosis efficiency. The only 
difference among the constructs was the length of the linker between the tyrosine-
containing BTAM region and Shp2. As mentioned earlier, the activation of iSNAP-Shp2 
was relying on the autoinhibitory N-SH2 domains in Shp2 to bind to the BTAM and 
exposing the enzymatic PTP domain [24]. 17mer has the shortest linker length among all 
the linkers, and the data demonstrated that the phagocytic power of RAW264.7 
transfected with SIRPα-Shp2-iSNAP-17mer was not increased, while those transfected 
with SIRPα-Shp2-iSNAP-34mer and SIRPα-Shp2-iSNAP-EV showed augmented 
phagocytosis. Therefore, the length of the linker played a role in the functionality of the 
size-reduced SIRPα-Shp2-iSNAP. With too short linker, the SH2 domains in Shp2 might 
not be able to bind to the BTAM due to structural hindrance, or the construct misfolded in 
the process so that the construct lost its function. For the first situation, the SH2 domains 
may still occlude the PTP domain, and Shp2 could not be activated properly, which may 
explain why the phagocytosis efficiency was not augmented for the macrophages 
transfected with SIRPα-Shp2-iSNAP-17mer. When the linker length was doubled by 
utilizing 34mer, the phagocytosis efficiency was increased significantly, and when the 
linker length became even longer, the efficiency decreased compared to 34mer but still 
significantly higher than the negative control group. This result indicated that the length 
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of the linker region influences the functionality of the SIRPα-Shp2-iSNAP constructs in 
macrophages, and an optimal length can be determined to maximize the functionality of 
this engineered protein and to successfully rewire the SIRPα-CD47 pathway.  
The sized-reduced SIRPα-Shp2-iSNAP, such as SIRPα-Shp2-iSNAP-34mer and 
SIRPα-Shp2-iSNAP-EV, showed enhanced engulfment toward opsonized RBCs as well, 
which indicated that they retained the rewiring and activating functions of the original 
SIRPα-Shp2-iSNAP. Therefore, with their reduced sizes, the efficiency of their lentiviral 
production and infection will greatly increase, which allows iSNAPs to be easier to apply 
in future experiments. 
The engulfment assay of the engineered PLDMs against opsonized RBCs and 
non-opsonized RBCs was also conducted. Overall, both the engineered PLDMs and the 
native PLDMs had increased phagocytosis of opsonized RBCs than that of non-
opsonized RBCs. After opsonization, engineered PLDMs with SIRPα-Shp2-iSNAP 
demonstrated more engulfment of RBCs than the other control groups. For non-
opsonized RBCs, SIRPα-Shp2-iSNAP did not show an elevated level of engulfment. By 
comparing the phagocytosis efficiency with and without antibody-opsonization, the 
results demonstrated that the macrophages expressing SIRPα-Shp2-iSNAP required 
antibody-mediation for their phagocytosis of CD47 expressing cells, which fulfill our 
goal of minimizing off-target effects for our engineered iSNAPs in immunotherapy.  
In addition, the results also indicated that the engineering of SIRPα/CD47 
pathway in human macrophages using SIRPα-Shp2-iSNAP can promote the antibody-
mediated tumor cell phagocytosis. Therefore, engineered iSNAPs with activating module 
Shp2 or Syk are capable of reprograming inhibitory SIRPα/CD47 pathway. Even with 
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overexpression of CD47 in tumor cells, since iSNAPs can reprogram the original anti-
phagocytic SIRPα/CD47 signaling into a pro-phagocytic one, CD47 ligation further 
promotes phagocytosis of engineered macrophages against those tumor cells. Thus, the 
engineered human macrophages with SIRPα-iSNAP working with mAbs that specifically 
target against tumor cells could lead to engulfment and eradication of tumor cells. At the 
same time, the function of mAbs could help minimize off-target effects against other 
CD47 expressing tissue cells.  
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2.4 Materials & Methods 
2.4.1 Plasmid construction 
The Shp2-iSNAP-LacZ was constructed first by using Gibson Assembly ((New 
England Biolabs) to fuse pSIN vector, SIRPα with BTAM instead of ITIM, LacZ, 
truncated human Shp2 and YPet together. Then by utilizing Golden Gate reaction relying 
on BsmBI sites in the construct, the LacZ region of Shp2-iSNAP-LacZ was replaced with 
17mer, 34mer and EV linker to create Shp2-iSNAP-17mer, -34mer and -EV. The Syk-
iSNAP-EV was constructed by fusing SIRPα without ITIM, ITAM region, EV linker, 
full-length Syk and YPet into pSIN vector using Gibson Assembly. The sequences of 
plasmids were verified by DNA sequencing. 
2.4.2 Cells and reagents 
RAW264.7, Toledo, HEK293T and HL60 were obtained from ATCC (Manassas, 
VA). RAW264.7 were maintained in medium containing DMEM (Gibco), 10% fetal 
bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA), 1x GlutaMAX (Thermo 
Fisher) and 1 x penicillin/streptomycin (Invitrogen). Toledo and HL60 were grown in 
RPMI 1640 (Invitrogen, Carlsbad, CA), added with 10% FBS, 1x GlutaMAX and 1% 
penicillin/streptomycin. These cells were cultured in 37°C humidified-incubator 
supplemented with 95% air and 5% CO2.  
2.4.3 RBC source 
Human peripheral blood samples were provided by VA San Diego Medical 
Center, San Diego, CA with an IRB-approved protocol (VA San Diego IRB# H150008). 
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2.4.4 Lentivirus production 
HEK293T cells were transfected with pSIN vector carrying SIRPa-iSNAPs, the 
packaging plasmid pSPAX2, and the envelope-encoding plasmid pMD.G by using 
Lipofectamine 2000 (Life technologies) [44]. After 72 hours culture, the media 
containing lentivirus were harvested and centrifuged at 1250 rpm for 5 minutes. Then, the 
supernatant was filtered through a 0.45 um syringe filter (Merck Millipore ltd.), and 
PEG-itTM (System Biosciences) were added to precipitate the virus. The mixture was 
shaken at 4 °C overnight, which was centrifuged at 1500 g for 30 minutes the next day to 
obtain virus pellet. The pellet was suspended with DMEM medium for infection. 
2.4.5 Electroporation of macrophages  
SIRPa-iSNAPs were introduced into RAW 264.7 by electroporation. 3 x 106 RAW 
264.7 were re-suspended in 220 µl of RPMI 1640 and added with 15 µg plasmids. Then 
the cell were electroporated in 4mm cuvette (Genesee Scientific Inc.) (250V, 950 mF, ∞ 
Ω), and they were cultured in 2 mL of DMEM with 10% FBS and 1 x GlutaMAX. 
2.4.6 Monocytic differentiation 
HL60 cells were transduced with concentrated lentivirus, and they were counted 
using a haemocytometer, and 1 x 106/ 3 mL cells were used in each 35 mm dishes 
(Thermo). Then, these cells are treated immediately with 20 ng/mL of 12-O-
tetradecanoylphorbol-l3-acetate (PMA) (Sigma-Aldrich) for 72 hrs, and the differentiated 
macrophages were used for phagocytosis assay. 
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2.4.7 Phagocytosis assay  
For phagocytosis assays, transfected macrophages were plated in 60 mm dishes 
(Thermo). RBCs and Toledo were washed twice PBS, and incubated with 1 µM and 0.3 
µM CellTrackerTM Deep Red dye (Life technologies) respectively in PBS for an hour at 
37°C. Then, extra dye was washed away by two times of wash with PBS plus 0.5% FBS, 
and the cells were resuspended in PBS plus 0.5% FBS. 
RBCs were opsonized by rabbit anti-hRBC IgG (0.5 µg/ml) (Cambridge, USA), and 
Toledo cells were opsonized by rituximab (ImClone LLC.). Then, labeled and opsonized 
RBCs were incubated with RAW264.7 at a ratio of 10:1 for 30 minutes in the incubator. 
After incubation with the macrophage, RBCs that were not engulfed were removed by 
washing with PBS plus 0.5% FBS twice and lysed by adding ACK buffer (NH4Cl 31 
mM, KHCO3 2 mM, EDTA 20 µM) for 1 minute.  
For Toledo cells, labeled cells and rituximab (10 µg/ml) were added together to 
PLDMs at a ratio of 10:1 and incubate at 37 °C for three hours. After incubation, Toledo 
cells that were not engulfed were removed by washing with PBS, and the removal 
efficacy was confirmed under microscope. At last, macrophages were detached by 
scratching the dish with cell lifters and kept in PBS with 0.5% FBS, which were read by 
flow cytometer for phagocytosis efficiency. 
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2.4.8 Flow cytometry  
Engineered macrophages had YPet expression, which has excitation of 488 nm 
and emission of 575/26 nm. Thus, these cells were measured by flow cytometry and 
gated. Then, the signal of engulfed cells (Deep Red, Ex:640 nm, Em:660/20 nm) were 
measured among the engineered macrophage population, and the average signal intensity 
was calculated to determine the phagocytosis efficiency.
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